Association of CMV DNAemia with Long-Term Mortality in a Randomized Trial of Preemptive Therapy (PET) and Antiviral Prophylaxis (AP) for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative (D+R-) Liver Transplant Recipients.
Lakshin KumarSayan DasguptaCristina Murray-KrezanNina SinghRobert M RakitaCynthia E FisherAjit P LimayePublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
We report a post-hoc analysis of the association of CMV DNAemia with long-term mortality in a randomized trial of CMV pre-emptive therapy vs. antiviral prophylaxis in D+R- liver transplant recipients. CMV DNAemia at 6- and 12-months post-transplant was associated with increased mortality even when adjusting for assigned intervention.